AARD Stock Forecast & Price Target

Aardvark Therapeutics Inc is strategically positioned for a positive financial outlook, particularly following the FDA's approval to lower the eligibility criteria for its Phase 3 HERO trial of ARD-101 in Prader Willi Syndrome (PWS) from age 10 to 7, thus expanding the potential patient population. The company's continued focus on developing oral gut-restricted small-molecule therapeutics, especially amid the significant opportunities presented by the less-than-optimal injectable GLP-1 drugs, underscores its innovative potential within the metabolic disease market. Additionally, while the likelihood of success for ARD-101 has been adjusted to 50%, the anticipated timeline for positive topline data remains encouraging, as the trial is reportedly more than halfway enrolled and expected to yield results by Q3 2026.

Aardvark Therapeutics faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential delays and uncertainties related to its lead product candidate, ARD-101. The company has acknowledged the possibility of a 10- to 11-month delay in the HERO program timeline, compounded by risks such as negative clinical results in its Phase 3 trial and difficulties in obtaining timely regulatory approval. Additionally, the landscape presents broader risks including competition in the PWS market, financial dilution concerns, and the impact of potential drug pricing reforms, all of which could adversely affect investor confidence and the company's financial stability.